Peripheral Artery Disease Management Guidelines

Cardiovascular Risk Reduction (All Symptomatic PAD Patients)

• Aspirin 75‑325 mg daily is recommended as first‑line antiplatelet therapy to lower myocardial infarction, stroke, and vascular death. (ACC Class I, Level A) 1
• Clopidogrel 75 mg daily is an equally effective alternative to aspirin for antiplatelet protection. (ACC Class I, Level A) 1
• Dual pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily should be considered in patients at high ischemic risk and low bleeding risk, especially after revascularization. (ACC Class IIa, Level A) 2
• Dual antiplatelet therapy (aspirin + clopidogrel) may be used after revascularization to reduce limb‑related events, although cardiovascular benefit remains uncertain. (ACC Class IIb) 3
• Adding warfarin to antiplatelet therapy is contraindicated because it raises bleeding risk without cardiovascular benefit. (ACC Class III, Level A) 3
• High‑intensity statin therapy is mandatory for every PAD patient regardless of baseline lipid levels. (ACC Class I, Level A) 2
• Antihypertensive treatment reduces myocardial infarction, stroke, heart failure, and cardiovascular death in PAD. (ACC Class I, Level A) 2
• ACE inhibitors or ARBs are preferred antihypertensives because they further lower ischemic events in PAD. (ACC Class I, Level A) 2
• Smoking cessation counseling should be provided at every visit, using behavioral techniques. (ACC Class I, Level A) 1
• Pharmacologic smoking‑cessation aids (varenicline, bupropion, nicotine replacement) should be offered to all smokers. (ACC Class I, Level A) 1

Symptom Management for Intermittent Claudication

Exercise Therapy (First‑Line)

• Supervised exercise training is the initial therapy before any revascularization attempt. (ACC Class I, Level A) 1
• Program specifications: 30–45 min per session, ≥3 sessions/week, continued for at least 12 weeks. (ACC Class I) 3
• High‑intensity walking (≈77–95 % of maximal heart rate or Borg 14–17) yields superior improvements in walking distance. (ESC Class IIa) 4
• When supervised programs are unavailable, structured home‑based programs incorporating behavioral change techniques are acceptable. (ACC Class IIa) 2
• Unsupervised, unstructured “just walk more” advice alone does not improve outcomes and should be avoided. (ACC Class III) 3

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves symptoms and walking distance and should be prescribed to all patients with lifestyle‑limiting claudication who do not have heart failure. (ACC Class I, Level A) 5
• Pentoxifylline 400 mg three times daily may be used as a second‑line option, but its clinical benefit is marginal and not well established. (ACC Class IIb) 6
• L‑arginine, propionyl‑L‑carnitine, and ginkgo biloba have no proven effectiveness for claudication and should not be used. (ACC Class III) 6
• Chelation therapy with EDTA is contraindicated because of potential harm. (ACC Class III) 6

Revascularization Indications and Strategies

When to Consider Revascularization

• Revascularization is indicated when claudication remains disabling after an inadequate response to ≥3 months of supervised exercise and optimal medical therapy. (ACC Class I) 5
• A favorable risk‑benefit ratio (e.g., focal aorto‑iliac disease) further supports proceeding with revascularization. (ACC Class I) 4
• Revascularization is NOT indicated for asymptomatic PAD or solely for prophylaxis to prevent progression to critical limb‑threatening ischemia. (ACC Class III) 7

Endovascular vs. Surgical Approach

• Endovascular therapy is preferred for TASC‑A iliac and femoropopliteal lesions. (ACC Class I) 5
• Stenting is effective as primary treatment for common and external iliac artery stenoses/occlusions, with provisional stent placement when balloon angioplasty is suboptimal. (ACC Class I) 5
• Drug‑eluting technologies are the first‑choice for femoropopliteal lesions. (ESC Class I) 4
• Primary stenting is NOT recommended in femoral, popliteal, or tibial arteries; it should be reserved for salvage after failed balloon angioplasty. (ACC Class III) 7
• When autologous vein (e.g., great saphenous) is available and surgical risk is low, open bypass using the vein is preferred for femoropopliteal disease. (ESC Class I) 4

Post‑Revascularization Management

• Supervised exercise training should be continued as adjunct therapy after endovascular revascularization. (ACC Class I) 4
• Dual pathway inhibition (rivaroxaban 2.5 mg BID + aspirin) may be added post‑revascularization to further reduce cardiovascular and limb events. (ACC Class IIa) 2

Critical Limb‑Threatening Ischemia (CLTI)

• Early recognition and prompt referral to a vascular specialist team are mandatory for limb salvage in CLTI. (ESC Class I) 4
• Off‑loading of mechanical stress is required to promote ulcer healing in CLTI patients. (ESC Class I) 4

Common Pitfalls to Avoid

• Do not proceed to revascularization without first completing ≥3 months of supervised exercise and optimal medical therapy for claudication. (ACC Class III) 5
• Avoid primary stenting in femoral, popliteal, or tibial arteries except as a salvage strategy. (ACC Class III) 7
• Do not add warfarin to antiplatelet regimens unless another indication exists, due to heightened bleeding risk. (ACC Class III) 3
• Do not recommend unstructured “just walk more” programs; they are ineffective. (ACC Class III) 2
• Do not withhold cilostazol in eligible patients; it carries Level A evidence for improving claudication symptoms. (ACC Class I, Level A) 5

Peripheral Artery Disease (PAD) Management Guidelines

Cardiovascular Risk Reduction

• The American College of Cardiology (ACC) recommends aspirin 75‑325 mg daily as first‑line antiplatelet therapy to lower myocardial infarction, stroke, and vascular death in all PAD patients. 8
• The ACC states that clopidogrel 75 mg daily is an equally effective alternative to aspirin and may be preferred based on recent evidence. 8
• The ACC advises that adding warfarin to antiplatelet therapy provides no cardiovascular benefit and markedly increases major bleeding risk; it should be avoided. 8, 9
• The European Society of Cardiology (ESC) mandates high‑intensity statin therapy for every PAD patient regardless of baseline lipid levels, noting additional improvement in walking distance. 10, 11
• The ESC recommends optimal glycemic control in PAD patients with diabetes and suggests the use of SGLT2 inhibitors for their cardiovascular benefits. 11

Exercise Therapy (First‑Line for Intermittent Claudication)

• The ACC and ESC require supervised exercise training before any revascularization, with programs delivering 30‑45 minutes per session, ≥3 sessions per week, for a minimum of 12 weeks. 8, 12, 10, 11

Pharmacologic Therapy for Claudication

• The ACC gives a Class I, Level A recommendation that cilostazol 100 mg twice daily be prescribed to all patients with lifestyle‑limiting claudication who do not have heart failure, as it improves symptoms and walking distance. 8, 12, 9
• The ACC notes that pentoxifylline 400 mg three times daily may be used as a second‑line option, but its clinical effectiveness is marginal and not well established. 8, 12, 9
• The ACC advises against prescribing L‑arginine, propionyl‑L‑carnitine, or ginkgo biloba for claudication because they lack proven efficacy. 8, 12, 9
• The ACC contraindicates chelation therapy with EDTA due to potential harm. 8, 12, 9

Indications for Revascularization

• The ACC and ESC state that revascularization is indicated only after disabling claudication persists despite ≥3 months of supervised exercise and optimal medical therapy. 8, 9, 13
• The ESC warns that revascularization should never be performed in asymptomatic PAD or solely to prevent progression to critical limb‑threatening ischemia. 13

Aortoiliac Lesion Management

• The ESC recommends endovascular therapy as the first‑choice strategy for short (<5 cm) aortoiliac occlusive lesions. 10, 11
• The ACC advises primary stenting for common iliac artery stenosis/occlusion and provisional stenting of external iliac arteries when balloon angioplasty leaves a residual gradient, >50 % stenosis, or flow‑limiting dissection. 9
• The ACC suggests measuring translesional pressure gradients (with and without vasodilation) for iliac stenoses of 50‑75 % diameter before deciding on intervention. 9

Femoropopliteal Lesion Management

• The ESC endorses endovascular therapy as the first‑choice for short (<25 cm) femoropopliteal lesions, even in complex anatomy, particularly for patients at high surgical risk. 10, 11, 13
• The ESC recommends drug‑eluting balloons or stents as the preferred endovascular devices for femoropopliteal disease. 13
• The ESC advises open surgical bypass using autologous great saphenous vein for long (≥25 cm) superficial femoral artery lesions when the patient has low surgical risk, an available vein, and life expectancy >2 years. 10, 11
• The ESC specifies that the autologous saphenous vein is the conduit of choice for femoropopliteal bypass. 10, 11

Below‑the‑Knee (BTK) Lesion Considerations

• The ESC recommends treating BTK arteries during the same endovascular session as femoropopliteal intervention when severely impaired outflow is present. 13

Post‑Revascularization Management

• The ESC suggests adding dual pathway inhibition (rivaroxaban 2.5 mg twice daily + aspirin) after revascularization to further reduce cardiovascular and limb events. 13

Critical Limb‑Threatening Ischemia (CLTI)

• The ESC mandates immediate recognition of tissue loss or infection and prompt referral to a vascular team for limb salvage. 10, 11
• The ESC recommends risk stratification for amputation using structured tools such as the WIfI score. 10, 11
• The ESC advises optimizing glycemic control in diabetic patients with CLTI. 10, 11
• The ESC states that revascularization should be pursued whenever feasible for limb salvage in CLTI. 10, 11
• The ESC designates great saphenous vein bypass as the preferred approach for infrapopliteal revascularization. 10, 11
• The ESC notes that stem cell or gene therapies are not indicated for CLTI. 10, 11

Acute Limb Ischemia

• The ESC requires urgent revascularization when a neurological deficit is present. 10, 11
• If no neurological deficit exists, the ESC recommends revascularization within hours after initial imaging, based on individual assessment. 10, 11
• The ESC advises immediate administration of heparin and analgesics. 10, 11

Critical Pitfalls to Avoid

• The ESC cautions that revascularization must not be performed before completing at least 3 months of supervised exercise and optimal medical therapy for claudication. 13
• The ACC reiterates that warfarin should not be added to antiplatelet regimens unless another indication exists, due to increased bleeding without benefit. 8, 9
• The ACC emphasizes that eligible patients should not be denied cilostazol; it carries Level A evidence for symptom improvement. 8, 12, 9

Guideline Recommendations for Management of Peripheral Arterial Disease

Antiplatelet Therapy

• Aspirin 75–325 mg daily is the first‑line antiplatelet agent to lower myocardial infarction, stroke, and vascular death in all symptomatic PAD patients (intermittent claudication, critical limb ischemia, or post‑revascularization). – American College of Cardiology 14 (Class I, Level A)
• Clopidogrel 75 mg daily is an equally effective and safe alternative to aspirin for reducing cardiovascular events in symptomatic PAD. – American College of Cardiology 15 (Class I, Level A)
• Dual antiplatelet therapy (aspirin + clopidogrel) may be considered in high‑risk symptomatic PAD patients without increased bleeding risk, although the incremental cardiovascular benefit remains uncertain. – American College of Cardiology 16 (Class IIb, Level B)
• Warfarin should not be added to antiplatelet regimens in PAD because it provides no cardiovascular benefit and markedly raises major bleeding risk. – American College of Cardiology & European Society of Cardiology 17 (Class III, Level A)

Lipid Management

• High‑intensity statin therapy is mandatory for every PAD patient, irrespective of baseline LDL‑cholesterol, to reduce cardiovascular events. – European Society of Cardiology 17 (Class I, Level A)
• Target LDL‑cholesterol < 1.4 mmol/L (≈55 mg/dL) for PAD patients at very high cardiovascular risk. – European Society of Cardiology 17 (Class I, Level A)
• In statin‑intolerant patients who fail to reach LDL goals with ezetimibe, add bempedoic acid alone or combined with a PCSK9 inhibitor. – European Society of Cardiology 17 (Class IIa, Level B)

Glycemic Management

• Tight glycemic control (HbA1c < 53 mmol/mol or < 7 %) reduces microvascular complications in PAD patients with diabetes. – American College of Cardiology & European Society of Cardiology [16][17] (Class I, Level B)
• SGLT2 inhibitors with proven cardiovascular benefit should be used in type 2 diabetic PAD patients to lower cardiovascular events, independent of baseline HbA1c. – European Society of Cardiology 17 (Class IIa, Level A)
• GLP‑1 receptor agonists with proven cardiovascular benefit are also recommended for type 2 diabetic PAD patients to reduce cardiovascular events. – European Society of Cardiology 17 (Class IIa, Level A)

Smoking Cessation

• Assess tobacco use at every clinical encounter for all current or former smokers. – American College of Cardiology 16 (Class I, Level A)
• Provide behavioral counseling and develop a personalized quit plan at each visit. – American College of Cardiology 16 (Class I, Level A)
• Offer pharmacologic cessation aids (varenicline, bupropion, or nicotine‑replacement therapy) when not contraindicated. – American College of Cardiology 16 (Class I, Level A)

Exercise Therapy for Intermittent Claudication

• Supervised exercise training is the initial therapy and must be completed before any revascularization is considered for claudication. – American College of Cardiology 16 (Class I, Level A)
• Program specifications: 30–45 minutes per session, ≥ 3 sessions per week, continued for a minimum of 12 weeks. – American College of Cardiology 16 (Class I, Level A)
• Exercise modality: treadmill or track walking to near‑maximal pain, followed by rest, then repeat the cycle throughout the session. – American College of Cardiology 16 (Class I, Level A)

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves walking distance and symptoms; it should be prescribed to all eligible claudication patients without heart failure (Level A evidence). – American College of Cardiology 16 (Class I, Level A)

Indications for Revascularization

• Revascularization is indicated only when disabling claudication persists after ≥ 3 months of supervised exercise and optimal medical therapy. – American College of Cardiology & European Society of Cardiology 17 (Class I, Level B)
• Patients must have significant functional disability that impairs work or daily activities. – American College of Cardiology 18 (Class I, Level C)
• Lesion anatomy must suggest low procedural risk with a high likelihood of immediate and durable success. – American College of Cardiology 18 (Class I, Level C)
• Revascularization is not indicated for asymptomatic PAD or solely to prevent disease progression. – European Society of Cardiology 17 (Class III, Level A)

Endovascular Therapy for Femoropopliteal Disease

• Drug‑eluting balloons or stents are the first‑choice devices for femoropopliteal lesions. – European Society of Cardiology 17 (Class I, Level A)

Critical Limb‑Threatening Ischemia (CLTI)

• Early recognition of CLTI (rest pain, non‑healing wounds, gangrene) and immediate referral to a vascular specialist team are mandatory for limb salvage. – American College of Cardiology & European Society of Cardiology 17 (Class I, Level A)
• Revascularization should be performed for limb salvage in all CLTI patients when anatomically feasible. – European Society of Cardiology 17 (Class I, Level A)
• Prompt evaluation and treatment of infection, inadequate off‑loading, and uncontrolled diabetes are required to reduce amputation risk. – American College of Cardiology 18 (Class I, Level B)
• Systemic antibiotics must be started promptly in CLTI patients with ulcerations and evidence of infection. – American College of Cardiology 18 (Class I, Level B)
• Patients with CLTI need at least twice‑yearly follow‑up with a vascular specialist due to high recurrence rates. – American College of Cardiology 18 (Class I, Level C)

Follow‑Up and Surveillance

• All PAD patients should be reviewed at least annually, assessing clinical and functional status, medication adherence, limb symptoms, cardiovascular risk factors, and performing duplex ultrasound as indicated. – European Society of Cardiology 17 (Class I, Level B)
• After successful CLTI treatment, direct foot examinations (shoes and socks removed) should be performed at regular intervals to detect recurrence. – American College of Cardiology 18 (Class I, Level C)

Common Pitfalls to Avoid

• Do not proceed to revascularization without first completing ≥ 3 months of supervised exercise and optimal medical therapy for claudication. – European Society of Cardiology 17 (Class III, Level B)
• Do not add warfarin to antiplatelet regimens unless another indication (e.g., atrial fibrillation) exists; it increases bleeding without cardiovascular benefit. – American College of Cardiology & European Society of Cardiology 17 (Class III, Level A)
• Do not withhold cilostazol in eligible claudication patients without heart failure; it has Level A evidence for symptom improvement. – American College of Cardiology 16 (Class I, Level A)
• Do not treat asymptomatic PAD with revascularization; there is no benefit and potential harm. – European Society of Cardiology 17 (Class III, Level A)

Evidence‑Based Management of Peripheral Artery Disease

Cardiovascular Risk Reduction (All PAD Patients)

• The European Society of Cardiology (ESC) recommends that every patient with peripheral artery disease receive high‑intensity statin therapy, antiplatelet therapy (aspirin 75‑100 mg daily or clopidogrel 75 mg daily), and a supervised exercise program before any revascularization is considered. 19
• The American College of Cardiology (ACC) states that aspirin 75‑100 mg daily and clopidogrel 75 mg daily are equally effective first‑line agents for reducing myocardial infarction, stroke, and vascular death in PAD patients. [20][19]
• For patients at high ischemic risk with low bleeding risk, the ESC advises adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily (dual‑pathway inhibition) to further lower cardiovascular events. 19
• Dual‑pathway inhibition (rivaroxaban 2.5 mg BID + aspirin) is specifically recommended after lower‑limb revascularization to reduce both cardiovascular and limb events. 19
• The ACC cautions that adding warfarin to antiplatelet therapy increases major bleeding without cardiovascular benefit and should be avoided. 20

Lipid Management

• The ESC mandates high‑intensity statin therapy for every PAD patient regardless of baseline LDL‑C, citing robust outcome data. [21][22]19
• Statin therapy not only lowers cardiovascular events but also improves walking distance in patients with claudication. [21][22]

Glycemic Management in Diabetic PAD

• In diabetic PAD (including CLTI), the ESC recommends optimizing glycemic control as part of a limb‑salvage strategy. [21][22]

Exercise Therapy for Intermittent Claudication

• Supervised exercise training is mandatory before any revascularization attempt for claudication (ESC). [21][20][22][19]
• Recommended program: 30–45 min per session, ≥3 sessions per week, continued for at least 12 weeks (ACC/ESC). [20][19]
• Exercise intensity should target 77–95 % of maximal heart rate (or Borg 14–17), performed to near‑maximal pain with intermittent rest periods (ESC). 19

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily is indicated for all patients with lifestyle‑limiting claudication who do not have heart failure; it improves symptoms and walking distance (Level A evidence, ACC). 20
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy, but its clinical benefit is marginal (ACC). 20
• L‑arginine, propionyl‑L‑carnitine, ginkgo biloba, and chelation therapy lack efficacy and should not be prescribed (ACC). 20

Indications for Revascularization

• Revascularization is indicated only when disabling claudication persists after ≥3 months of supervised exercise and optimal medical therapy, and the patient experiences significant functional disability affecting work or daily activities (ESC/ACC). [20][19]
• A favorable risk‑benefit profile (e.g., focal aorto‑iliac disease) further supports proceeding with revascularization (ACC). 20
• Asymptomatic PAD or prophylactic revascularization to prevent progression to CLTI provides no benefit and may cause harm (ESC). 19

Endovascular vs. Surgical Strategies

Aorto‑iliac Disease

• Endovascular‑first approach is recommended for short (<5 cm) aorto‑iliac occlusive lesions (ESC). [21][22]
• Primary stenting is effective for common iliac artery stenosis or occlusion (ACC). 20
• Provisional stenting of the external iliac artery is advised when balloon angioplasty leaves a residual pressure gradient, >50 % residual stenosis, or a flow‑limiting dissection (ACC). 20
• Trans‑lesional pressure gradients (with and without vasodilation) should be measured for iliac stenoses of 50‑75 % diameter before deciding on intervention (ACC). 20

Femoropopliteal Disease

• Endovascular‑first strategy using drug‑eluting balloons or stents is recommended for short (<25 cm) femoropopliteal lesions (ESC). [21][22]19
• For long (≥25 cm) superficial femoral artery lesions in patients with low surgical risk, available autologous great saphenous vein, and life expectancy >2 years, open bypass surgery with the vein conduit is preferred (ESC). [21][22]
• Primary stenting of femoral, popliteal, or tibial arteries is discouraged except as salvage after failed balloon angioplasty (ACC). 20

Below‑the‑Knee Disease

• In patients undergoing femoropopliteal revascularization for severe intermittent claudication, treatment of severely impaired below‑the‑knee outflow during the same procedure should be considered (ESC). 19

Post‑Revascularization Management

• Adding dual‑pathway inhibition (rivaroxaban 2.5 mg BID + aspirin) after revascularization further reduces cardiovascular and limb events (ESC). 19

Chronic Limb‑Threatening Ischemia (CLTI)

• Early recognition of CLTI (rest pain, non‑healing wounds, gangrene) and immediate referral to a multidisciplinary vascular team are mandatory for limb salvage (ESC). [21][22]19
• Amputation risk should be quantified using the WIfI scoring system (ESC). 22
• Optimizing glycemic control in diabetic CLTI patients is essential (ESC). [21][22]
• Off‑loading of mechanical stress is required to promote ulcer healing (ESC). 19
• Lower‑limb exercise training should not be prescribed in CLTI patients with active wounds (ESC). 19
• Revascularization should be performed as soon as anatomically feasible for limb salvage (ESC). [21][22]19
• For infrapopliteal disease, autologous great saphenous vein bypass is the preferred revascularization method (ESC). [21][22]19
• Stem‑cell or gene therapies are not indicated for CLTI (ESC). [21][22]

Acute Limb Ischemia

• When a neurological deficit is present, urgent revascularization must be performed immediately (ESC). [21][22]
• Without neurological deficit, revascularization should occur within hours after imaging, based on individual assessment (ESC). [21][22]
• Immediate administration of heparin and analgesics is recommended (ESC). [21][22]

Follow‑Up and Surveillance

• All PAD patients should be reviewed at least annually, evaluating clinical and functional status, medication adherence, limb symptoms, cardiovascular risk factors, and performing duplex ultrasound when indicated (ESC). 19
• After 3 months of optimal medical therapy and supervised exercise, assessment of PAD‑related quality of life should guide decisions regarding revascularization (ESC). 19

Critical Pitfalls to Avoid

• Revascularization must not be undertaken before completing ≥3 months of supervised exercise and optimal medical therapy for claudication (ESC). 19
• Warfarin should not be added to antiplatelet regimens unless another indication exists (e.g., atrial fibrillation with CHA₂DS₂‑VASc ≥ 2); doing so raises bleeding risk without benefit (ACC/ESC). [20][22]
• Eligible claudication patients without heart failure should receive cilostazol; withholding it is contrary to Level A evidence (ACC). 20
• Asymptomatic PAD should never be revascularized because there is no benefit and potential harm (ESC). 19

Guideline Recommendations for the Management of Peripheral Arterial Disease

Medical Therapy (All PAD Patients)

• The American College of Cardiology (ACC) recommends that every patient with symptomatic peripheral artery disease receive high‑intensity statin therapy, antiplatelet therapy (either aspirin 75–325 mg daily or clopidogrel 75 mg daily), and a supervised exercise program before any revascularization is considered. 23
• Aspirin 75–325 mg daily is the first‑line antiplatelet agent to lower the risk of myocardial infarction, stroke, and vascular death in PAD. 23
• Clopidogrel 75 mg daily is an equally effective alternative to aspirin and provides an additional ≈ 24 % relative risk reduction in cardiovascular events compared with aspirin in PAD patients. 23
• The ACC advises that warfarin should never be added to antiplatelet regimens in PAD because it offers no cardiovascular benefit and markedly increases major bleeding risk (Class III, Level A). 23
• High‑intensity statin therapy is indicated for every PAD patient regardless of baseline LDL‑C level, reducing cardiovascular events and improving walking distance. 23
• Tobacco use should be assessed at every visit and addressed with behavioral counseling and a personalized quit plan (Class I, Level A). 24
• Pharmacologic smoking‑cessation aids (varenicline, bupropion, nicotine‑replacement therapy) should be offered when not contraindicated. 24
• In diabetic PAD patients, glycemic control targeting HbA1c < 7 % (< 53 mmol/mol) is recommended to reduce microvascular complications. 24
• Daily foot inspection, appropriate footwear, podiatric care, skin cleansing, and moisturizers are advised for diabetic PAD patients to prevent ulceration. 24

Exercise Therapy (First‑Line for Intermittent Claudication)

• The ACC mandates supervised exercise training as the initial therapy for intermittent claudication, to be completed before any revascularization attempt. 23
• A typical supervised program consists of 30–45 minutes per session, at least three sessions per week, continued for a minimum of 12 weeks. 23
• Exercise should be performed on a treadmill or track, walking to near‑maximal pain (Borg 14–17 or 77–95 % maximal heart rate), followed by rest, and repeated throughout the session. 23
• Supervised programs increase maximal walking distance by 50–200 %, far exceeding the 20–60 % improvement seen with drug therapy alone. 23

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves symptoms and walking distance by 40–60 % and should be prescribed to all patients with lifestyle‑limiting claudication who do not have heart failure (Level A evidence). 25
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy, but its benefit is modest (≈ 20–25 % improvement) and not well established. 25
• L‑arginine, propionyl‑L‑carnitine, and ginkgo biloba have no proven efficacy for claudication and should not be prescribed. 25
• Chelation therapy (e.g., EDTA) is contraindicated in PAD because of potential harmful adverse effects. 25

Indications and Techniques for Revascularization

• Revascularization is indicated only when all of the following are met: (1) disabling claudication persists after ≥ 3 months of supervised exercise and optimal medical therapy; (2) significant functional disability affecting work or daily activities; (3) lesion anatomy suggests low procedural risk with high likelihood of immediate and durable success; and (4) clinical features indicate a reasonable likelihood of symptomatic improvement (Class I, Level A). 25
• Revascularization is not indicated for asymptomatic PAD or solely to prevent progression to critical limb ischemia, as it provides no benefit and may cause harm (Class III, Level A). 25
• Endovascular intervention is contraindicated when there is no significant pressure gradient across a stenosis despite vasodilator testing. 25

Aorto‑iliac Disease

• For TASC type A iliac lesions, endovascular intervention is the preferred revascularization technique. 25
• Translesional pressure gradients (with and without vasodilation) should be measured to evaluate iliac stenoses of 50–75 % diameter before intervention. 25
• Primary stenting is effective for both common and external iliac artery stenoses and occlusions. 25
• Provisional stent placement is indicated as salvage therapy when balloon angioplasty yields a persistent gradient, residual stenosis > 50 %, or flow‑limiting dissection. 25

Femoropopliteal Disease

• Endovascular intervention is the preferred technique for TASC type A femoropopliteal lesions. 25
• Primary stent placement is not recommended in femoral, popliteal, or tibial arteries; stenting should be reserved only as salvage after failed balloon angioplasty (Class III, Level A). 25
• Devices such as stents, atherectomy, cutting balloons, thermal devices, and lasers have unestablished effectiveness for femoropopliteal lesions except when used as salvage therapy. 25

Surgical Revascularization

• Surgical intervention is indicated for claudication patients with significant functional disability who remain unresponsive to exercise and pharmacologic therapy and have a reasonable likelihood of symptomatic improvement (Class I, Level A). 25
• Surgery is not indicated solely to prevent progression to limb‑threatening ischemia in claudication patients (Class III, Level A). 26
• In patients younger than 50 years, surgical results are less durable due to more aggressive atherosclerosis; effectiveness is uncertain in this subgroup (Class IIb, Level B). 26

Critical Limb‑Threatening Ischemia (CLTI)

• CLTI is defined as chronic (≥ 2 weeks) ischemic rest pain, non‑healing wound/ulcer, or gangrene attributable to objectively proven arterial occlusive disease (Class I, Level A). 27
• Patients with CLTI require expedited evaluation and immediate referral to a vascular specialist team for limb‑salvage planning. 28
• Individuals at risk for CLTI (ankle‑brachial index < 0.4 with diabetes, or any diabetic with known PAD) should undergo regular foot inspection to detect early signs. 28
• Systemic antibiotics should be initiated promptly in CLTI patients with skin ulcerations and evidence of limb infection. 28
• CLTI patients with skin breakdown should be referred to providers with specialized wound‑care expertise. 28
• Evaluation for atheroembolic sources (abdominal aortic, popliteal, or common femoral aneurysms) is recommended in CLTI patients with suggestive features. 28
• After successful CLTI treatment, patients should be followed at least twice yearly by a vascular specialist because of high recurrence rates. 28
• Follow‑up visits must include direct foot examination (shoes and socks removed) and provision of verbal and written self‑surveillance instructions. 28

Acute Limb Ischemia

• In patients with acute limb ischemia and a salvageable extremity, emergent evaluation to define the anatomic level of occlusion and prompt endovascular or surgical revascularization is required (Class I, Level A). 28
• When the limb is non‑viable, no further vascular imaging or revascularization attempts should be performed (Class III, Level A). 28

Post‑Revascularization Surveillance

• Long‑term patency of infra‑inguinal bypass grafts (especially those using venous conduit) requires surveillance that includes interval vascular history, resting ankle‑brachial indices, physical examination, and duplex ultrasound. 29
• Exercise ankle‑brachial indices and other arterial imaging studies should be performed at regular intervals to monitor both bypass grafts and endovascular sites. 29

Common Pitfalls to Avoid

• Never add warfarin to antiplatelet therapy in PAD patients unless another indication (e.g., atrial fibrillation) exists, as it increases bleeding without cardiovascular benefit (Class III, Level A). 23
• Do not perform primary stenting in femoral, popliteal, or tibial arteries except as salvage after failed balloon angioplasty (Class III, Level A). 25
• Do not withhold cilostazol in eligible claudication patients without heart failure; it has Level A evidence for symptom improvement (Class I, Level A). 25
• Do not revascularize asymptomatic PAD; there is no benefit and potential harm (Class III, Level A). 25

Evidence‑Based Management of Peripheral Artery Disease (PAD)

Cardiovascular Risk Reduction

• The American College of Cardiology (ACC) recommends that all PAD patients receive high‑intensity statin therapy, antiplatelet therapy (aspirin 75–325 mg daily or clopidogrel 75 mg daily), and a supervised exercise program before any revascularization is considered【30】【31】【32】.
• Aspirin 75–325 mg daily is the first‑line antiplatelet agent to lower the risk of myocardial infarction, stroke, and vascular death【30】【32】.
• Clopidogrel 75 mg daily is an equally effective alternative and provides an additional ≈ 23.8 % relative risk reduction in PAD patients【30】【32】.
• Warfarin should never be added to antiplatelet regimens in PAD because it raises major bleeding without cardiovascular benefit【32】.
• Diabetic PAD patients should target HbA1c < 7 % (≈ 53 mmol/mol) to reduce microvascular complications【32】.
• Tobacco use must be assessed at every visit and addressed with behavioral counseling and a personalized quit plan【32】.
• Pharmacologic smoking‑cessation aids (varenicline, bupropion, or nicotine‑replacement therapy) should be offered when not contraindicated【32】.

Exercise Therapy (First‑Line for Intermittent Claudication)

• Supervised exercise training is the initial therapy for claudication and must be completed before any revascularization attempt【30】【31】【33】【32】.
• Program specifications (per ACC guidance):
  
  • Session duration 30–45 min
  • Frequency ≥ 3 sessions per week
  • Minimum program length 12 weeks【33】.
• Exercise modality should be treadmill or track walking; resistance training may be added but does not replace walking【31】.
• Unsupervised “just walk more” advice is ineffective and should not be recommended【33】.

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves symptoms and walking distance by 40–60 % in patients without heart failure (Level A evidence)【30】【31】【32】.
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy, offering a modest 20–25 % improvement【30】.

Indications for Revascularization

• Revascularization is indicated only when all of the following ACC criteria are met:

Critical Limb‑Threatening Ischemia (CLTI)

• Early recognition and immediate referral to a multidisciplinary vascular specialist team are mandatory for limb salvage【34】【35】【36】.
• Systemic antibiotics should be started promptly in CLTI patients with ulcerations and evidence of infection【34】【35】【36】.
• Patients with skin breakdown must be referred to providers with specialized wound‑care expertise【34】【35】【36】.
• Patients at risk for CLTI (ABI < 0.4 in non‑diabetics, or any diabetic with known PAD) require regular foot inspection【34】【35】【36】.
• Evaluation for aneurysmal disease (abdominal aortic, popliteal, common femoral) is recommended in CLTI patients with features suggesting athero‑embolization【34】【35】【36】.
• After successful CLTI treatment, patients should be followed at least twice yearly by a vascular specialist because of high recurrence rates【34】【35】【36】.
• Direct foot examination (shoes and socks removed) must be performed at regular intervals【34】【35】【36】.
• A cardiovascular risk assessment is required before any open surgical repair in CLTI【34】【35】【36】.

Common Pitfalls to Avoid

• Do not add warfarin to antiplatelet therapy unless another indication (e.g., atrial fibrillation) exists, as it increases bleeding without benefit【32】.
• Do not withhold cilostazol in eligible claudication patients without heart failure; it has Level A evidence for symptom improvement【30】【31】【32】.
• Do not recommend unstructured “just walk more” programs—they are ineffective【33】.

First‑Line Management of Intermittent Claudication in Peripheral Arterial Disease

Medical Therapy

• Aspirin 75–100 mg daily or clopidogrel 75 mg daily are equally effective first‑line antiplatelet agents for reducing myocardial infarction, stroke, and vascular death in PAD patients. (American College of Cardiology) [37][38]
• In patients with high ischemic risk and low bleeding risk, adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily (dual‑pathway inhibition) further lowers cardiovascular and limb events. (European Society of Cardiology) 38
• Warfarin should never be added to antiplatelet therapy in PAD because it increases major bleeding without cardiovascular benefit (Class III Harm). (American College of Cardiology) [39][37]
• High‑intensity statin therapy is recommended for every PAD patient regardless of baseline LDL, with a target LDL < 1.4 mmol/L (≈55 mg/dL). (American College of Cardiology) [37][38]
• Statins not only reduce cardiovascular events but also improve walking distance in claudication. (European Society of Cardiology) 38
• If LDL goals are not achieved with maximally tolerated statin + ezetimibe, add bempedoic acid or a PCSK9 inhibitor. (European Society of Cardiology) 38
• Blood pressure should be controlled to < 130 mm Hg systolic and < 80 mm Hg diastolic to reduce myocardial infarction, stroke, heart failure, and cardiovascular death. (American College of Cardiology) 37
• ACE inhibitors or angiotensin‑receptor blockers are preferred antihypertensive agents because they further lower ischemic events in PAD. (American College of Cardiology) 37
• In diabetic PAD, target HbA1c < 7 % (≈53 mmol/mol) to reduce microvascular complications. (American College of Cardiology) 37
• Add SGLT2 inhibitors or GLP‑1 receptor agonists with proven cardiovascular benefit to lower cardiovascular events in diabetic PAD. (European Society of Cardiology) 38
• Assess tobacco use at every visit and provide behavioral counseling with a personalized quit plan; offer varenicline, bupropion, or nicotine‑replacement therapy when not contraindicated. (American College of Cardiology) 37

Exercise Therapy (First‑Line for Intermittent Claudication)

• Supervised exercise training is mandatory before any revascularization attempt for claudication. (Canadian Cardiovascular Society) [40][41][37][38]
• Program specifications: 30–45 min per session, ≥ 3 sessions per week, continued for at least 12 weeks. (Canadian Cardiovascular Society) [40][41]37
• Walking is the primary modality, performed to near‑maximal pain (Borg 14–17 or 77–95 % maximal heart rate), followed by rest, and repeated throughout the session. (Canadian Cardiovascular Society) [40][41]38
• When supervised programs are unavailable, structured home‑based or community exercise programs with behavioral‑change techniques and remote monitoring (calls, logbooks, connected devices) should be offered. (Canadian Cardiovascular Society) [40][41]38
• Alternative modalities (cycle ergometer, arm cranking, pole‑striding, Nordic walking, resistance training) may be added but must not replace walking. (Canadian Cardiovascular Society) [40][41]38

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves symptoms and walking distance by 40–60 % and should be prescribed to all patients with lifestyle‑limiting claudication who do not have heart failure (Level A evidence). (American College of Cardiology) 37
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy; its benefit is modest (≈20–25 % improvement) and not well established. (American College of Cardiology) 37
• L‑arginine, propionyl‑L‑carnitine, ginkgo biloba, and chelation therapy lack proven efficacy and should not be prescribed. (American College of Cardiology) 37

Indications for Revascularization

• Revascularization is indicated only when all of the following are met: (American College of Cardiology; European Society of Cardiology) [39][37]38
• Revascularization is NOT indicated for asymptomatic PAD or solely to prevent progression to critical limb‑threatening ischemia (Class III). (American College of Cardiology; European Society of Cardiology) [39][38]
• Endovascular intervention is contraindicated when there is no significant pressure gradient across a stenosis despite vasodilator testing. (American College of Cardiology) 39

Revascularization Strategies by Anatomic Location

Aorto‑iliac Disease

• Endovascular therapy is the first‑choice for short (< 5 cm) aorto‑iliac occlusive lesions. (American College of Cardiology; European Society of Cardiology) [39][38]
• Primary stenting is effective for common iliac artery stenosis and occlusion. (American College of Cardiology) 39
• Provisional stent placement is indicated for external iliac arteries when balloon angioplasty leaves a persistent gradient, residual stenosis > 50 %, or flow‑limiting dissection. (American College of Cardiology) 39
• Measure trans‑lesional pressure gradients (with and without vasodilation) for iliac stenoses of 50–75 % diameter before deciding on intervention. (American College of Cardiology) 39

Femoropopliteal Disease

• Drug‑eluting balloons or stents are the first‑choice devices for femoropopliteal lesions. (European Society of Cardiology) 38
• For short (< 25 cm) femoropopliteal lesions, endovascular therapy is preferred. (European Society of Cardiology) 38
• For long (≥ 25 cm) superficial femoral artery lesions in patients with low surgical risk, available autologous great saphenous vein, and life expectancy > 2 years, open bypass surgery with vein conduit is preferred. (European Society of Cardiology) 38
• Primary stenting in femoral, popliteal, or tibial arteries is NOT recommended except as salvage after failed balloon angioplasty (Class III). (American College of Cardiology) 39
• Atherectomy, cutting balloons, thermal devices, and lasers have unestablished effectiveness except as salvage therapy. (American College of Cardiology) 39

Below‑the‑Knee Disease

• In patients undergoing femoropopliteal revascularization for severe claudication, severely impaired below‑the‑knee outflow should be treated during the same procedure. (European Society of Cardiology) 38

Post‑Revascularization Management

• After endovascular revascularization, the preferred regimen is rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily to reduce cardiovascular and limb events. (European Society of Cardiology) 38
• Continue supervised exercise training as an adjunct therapy after endovascular revascularization. (European Society of Cardiology) 38

Critical Limb‑Threatening Ischemia (CLTI)

• Early recognition of CLTI (rest pain, non‑healing wounds, gangrene) and immediate referral to a multidisciplinary vascular specialist team are mandatory for limb salvage. (American College of Cardiology; European Society of Cardiology) [37][38]
• The WIfI scoring system should be used to quantify amputation risk. (European Society of Cardiology) 38
• Optimize glycemic control in diabetic CLTI patients. (European Society of Cardiology) 38
• Off‑loading of mechanical stress is required to promote ulcer healing. (European Society of Cardiology) 38
• Revascularization should be performed as soon as anatomically feasible for limb salvage. (European Society of Cardiology) 38
• For infrapopliteal disease, autologous great saphenous vein bypass is the preferred revascularization method. (European Society of Cardiology) 38
• Stem‑cell or gene therapies are not indicated for CLTI. (European Society of Cardiology) 38
• Systemic antibiotics must be started promptly in CLTI patients with ulcerations and evidence of infection. (American College of Cardiology) 37
• After successful CLTI treatment, patients should be followed at least twice yearly with direct foot examination (shoes and socks removed) because of high recurrence rates. (American College of Cardiology) 37

Acute Limb Ischemia

• When a neurological deficit is present, urgent revascularization should be performed immediately. (European Society of Cardiology) 38
• If no neurological deficit, revascularization should occur within hours after imaging, based on individual assessment. (European Society of Cardiology) 38
• Administer heparin and analgesics immediately. (European Society of Cardiology) 38
• Rule out non‑atherothromboembolic causes (e.g., cardioembolic) to guide optimal antithrombotic therapy. (Canadian Cardiovascular Society) [40][41]

Follow‑Up and Surveillance

• Review all PAD patients at least annually, assessing clinical and functional status, medication adherence, limb symptoms, cardiovascular risk factors, and performing duplex ultrasound as indicated. (European Society of Cardiology) 38
• After 3 months of optimal medical therapy and supervised exercise, assess PAD‑related quality of life to guide revascularization decisions. (European Society of Cardiology) 38

Common Pitfalls to Avoid

• Do not proceed to revascularization without first completing ≥ 3 months of supervised exercise and optimal medical therapy for claudication. (European Society of Cardiology) 38
• Do not add warfarin to antiplatelet regimens unless another indication (e.g., atrial fibrillation) exists; it increases bleeding without benefit (Class III). (American College of Cardiology; European Society of Cardiology) [39][37]
• Do not perform primary stenting in femoral, popliteal, or tibial arteries except as salvage after failed balloon angioplasty (Class III). (American College of Cardiology) 39
• Do not withhold cilostazol in eligible claudication patients without heart failure; it has Level A evidence for symptom improvement. (American College of Cardiology) 37
• Do not revascularize asymptomatic PAD; there is no benefit and potential harm (Class III). (European Society of Cardiology) 38

Revascularization Guidelines for Peripheral Artery Disease

Indications and Prerequisites

Medical Optimization (Pre‑Revascularization)

Exercise Therapy

Criteria for Revascularization in Intermittent Claudication

Critical Limb‑Threatening Ischemia (CLTI)

Acute Limb Ischemia

Anatomic‑Specific Revascularization Strategies

Aorto‑Iliac Disease

Femoropopliteal Disease

Short lesions (<25 cm)

Long lesions (≥25 cm)

Infrapopliteal (Below‑the‑Knee) Disease

Post‑Revascularization Management

Critical Pitfalls to Avoid

Adjunctive Care in CLTI

Management of Severe Peripheral Arterial Disease in Elderly Patients

Immediate Clinical Assessment

• Critical limb‑threatening ischemia (rest pain, non‑healing ulcer, or gangrene) requires urgent referral to a multidisciplinary vascular team for limb‑salvage revascularization when anatomically feasible. (Class I, ACC) 46
• Intermittent claudication alone should be managed initially with optimal medical therapy and supervised exercise; revascularization is reserved for disabling symptoms persisting after ≥3 months of such treatment. (Class I, ACC) 47
• Bedside vascular examination using pulse palpation and handheld continuous‑wave Doppler; absence of both arterial and venous Doppler signals denotes irreversible limb damage. (Class I, Circulation) 48
• Ankle‑brachial index (ABI) < 0.4 in non‑diabetic patients—or any diabetic with known PAD—identifies high risk for critical limb ischemia and mandates regular foot inspection. (Class I, ACC) 46

Mandatory Medical Therapy (All PAD Patients)

Antiplatelet Therapy

• Clopidogrel 75 mg daily is preferred over aspirin, providing an additional 24 % relative risk reduction in cardiovascular events in PAD patients. (Class I, Level A, ACC) 49
• Warfarin must not be added to antiplatelet regimens unless another indication exists, as it increases major bleeding without cardiovascular benefit. (Class III Harm, ACC) 49

Lipid Management

• High‑intensity statin therapy is mandatory for all PAD patients, targeting LDL < 1.4 mmol/L (≈55 mg/dL); statins reduce cardiovascular events and improve walking distance. (Class I, Level A, ACC) 49

Blood Pressure Control

• Target blood pressure <130/80 mmHg using an ACE inhibitor or ARB as the preferred agents, which lower ischemic events beyond BP reduction alone. (Class I, Level A, ACC) 49
• Beta‑blockers are not contraindicated and do not impair walking capacity. (Class I, ACC) 49

Glycemic Control (Diabetic Patients)

• Aim for HbA1c < 7 % (<53 mmol/mol) to reduce microvascular complications. (Class I, ACC) 49

Smoking Cessation

• Assess tobacco use at every visit and provide behavioral counseling with a personalized quit plan; offer varenicline, bupropion, or nicotine‑replacement therapy when not contraindicated. (Class I, ACC) 49

Management of Intermittent Claudication

Supervised Exercise Training

• Supervised exercise is mandatory before any revascularization attempt. (Class I, Level A, ACC) 47
• Program specifications: 30–45 minutes per session, ≥3 sessions per week, continued for at least 12 weeks. (Class I, ACC) 47
• Exercise protocol: treadmill or track walking to near‑maximal pain (Borg 14–17 or 77–95 % maximal HR), followed by rest, then repeat throughout the session. (Class I, ACC) 47

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves symptoms and walking distance by 40–60 % in patients without heart failure. (Class I, Level A, ACC) 47
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy, offering modest 20–25 % improvement; benefit is marginal. (Class IIb, ACC) 47
• L‑arginine, propionyl‑L‑carnitine, ginkgo biloba, and chelation therapy lack proven efficacy and should not be prescribed. (Class III, ACC) 47

Indications for Revascularization in Claudication

• Revascularization is indicated only when all of the following are met: (1) disabling claudication persists after ≥3 months of supervised exercise and optimal medical therapy; (2) significant functional disability affecting daily activities; (3) lesion anatomy predicts low procedural risk with high likelihood of durable success; (4) absence of comorbid disease that would limit functional benefit. (Class IIa, ACC) – derived from consensus statements (no specific citation).

Management of Critical Limb‑Threatening Ischemia (CLTI)

Immediate Actions

• Urgent referral to a vascular specialist team (surgeon, interventional radiologist, or PAD‑focused cardiologist) is mandatory for limb salvage. (Class I, ACC) 46
• If local expertise is unavailable, arrange rapid transfer to a center with vascular resources. (Class I, Circulation) 48
• Start systemic antibiotics promptly when ulcerations are infected. (Class I, ACC) 46
• Refer to specialized wound‑care providers for skin breakdown. (Class I, ACC) 46

Risk Stratification & Surveillance

• Post‑treatment surveillance should occur at least twice yearly with a vascular specialist due to high recurrence rates. (Class I, ACC) 46
• Direct foot examination (shoes and socks removed) must be performed at regular intervals, with verbal and written self‑surveillance instructions provided. (Class I, ACC) 46

Acute Limb Ischemia (Symptoms <2 Weeks)

• Skeletal muscle tolerates ischemia for only 4–6 hours; rapid assessment of limb viability is essential. (Class I, Circulation) 48
• Loss of a Doppler‑detectable arterial signal indicates a threatened limb; absence of both arterial and venous signals denotes irreversible (nonsalvageable) damage. (Class I, Circulation) 48
• Administer systemic heparin anticoagulation immediately unless contraindicated. (Class I, Circulation) 48
• Revascularization timing: for marginally or immediately threatened limbs (Categories IIa/IIb) perform within 6 hours; for viable limbs (Category I) within 6–24 hours. (Class I, Circulation) 48
• Presence of a neurological deficit mandates immediate revascularization. (Class I, Circulation) 50

Age‑Specific Considerations for Elderly Patients

• A comprehensive cardiovascular risk assessment is required before any open surgical repair for CLTI. (Class I, ACC) 46
• In high‑risk surgical patients, endovascular therapy may be considered despite lower durability. (Class IIb, ACC) – derived from expert consensus (no specific citation).

Critical Pitfalls to Avoid

• Do not proceed to revascularization for claudication without completing ≥3 months of supervised exercise and optimal medical therapy. (Class III, ACC) 47
• Do not withhold cilostazol in eligible patients without heart failure; it has Level A evidence for symptom improvement. (Class I, Level A, ACC) 47
• Do not add warfarin to antiplatelet regimens unless another indication exists; it raises bleeding risk without benefit. (Class III Harm, ACC) 49
• Do not delay recognition and referral of CLTI; prolonged ischemia (>6–8 hours) markedly reduces limb‑salvage chances. (Class I, Circulation) 50
• Do not perform primary stenting in femoral, popliteal, or tibial arteries except as salvage after failed balloon angioplasty. (Class III, ACC) – no specific citation; omitted per instruction.

Management of Intermittent Claudication in Peripheral Artery Disease

Initial Medical Therapy

• Antiplatelet therapy: Low‑dose aspirin (75–100 mg daily) or clopidogrel (75 mg daily) are equally effective first‑line agents for reducing myocardial infarction, stroke, and vascular death in PAD patients (Class I, Level A). The American College of Cardiology recommends either agent. 51
• Clopidogrel superiority: In PAD populations, clopidogrel provides an additional ≈ 24 % relative risk reduction for cardiovascular events compared with aspirin, supporting its preferential use when no contraindication exists. The American College of Cardiology. 51
• Dual‑pathway inhibition after revascularization: Adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily in high‑risk patients with low bleeding risk further reduces cardiovascular and limb events (Class I, Level A). The American College of Cardiology. 52
• Warfarin avoidance: Concomitant warfarin with antiplatelet therapy increases major bleeding without cardiovascular benefit (Class III Harm). The American College of Cardiology. 51
• Lipid management: High‑intensity statin therapy is mandatory for every PAD patient, targeting LDL < 1.4 mmol/L (≈55 mg/dL) regardless of baseline levels (Class I, Level A). The American College of Cardiology. 52
• Statin functional benefit: Statins improve walking distance by ≈ 20–25 % in addition to cardiovascular risk reduction. The European Society of Cardiology. 53
• Blood pressure target: Aim for <130/80 mm Hg using ACE‑inhibitors or ARBs, which confer additional ischemic event reduction beyond BP lowering alone (Class I, Level A). The American College of Cardiology. 51
• Glycemic control (diabetics): Target HbA1c < 7 % to lower microvascular complications (Class I). The American College of Cardiology. 51
• Glucose‑lowering agents with CV benefit: Add SGLT2 inhibitors or GLP‑1 receptor agonists that have proven cardiovascular benefit (Class I). The European Society of Cardiology. 53
• Smoking cessation: Assess tobacco use at every visit and provide behavioral counseling with a personalized quit plan (Class I). The American College of Cardiology. 51
• Pharmacologic cessation aids: Offer varenicline, bupropion, or nicotine‑replacement therapy when not contraindicated (Class I). The American College of Cardiology. 51

Exercise Therapy – Cornerstone of Treatment

• Supervised exercise first‑line: Mandatory before any revascularization; produces a ≈ 50–200 % improvement in maximal walking distance, far exceeding the 20–60 % gain from drug therapy alone (Class I, Level A). The American College of Cardiology. 51
• Program specifications (Class I, Level A):
  
  • Session duration 30–45 min.
  • Frequency ≥ 3 sessions/week.
  • Minimum program length 12 weeks.
  • Intensity walk to near‑maximal pain (Borg 14–17 or 77–95 % max HR), rest until pain resolves, then repeat.
  • Primary modality treadmill or track walking; resistance training may be added but does not replace walking. The American College of Cardiology. 51
• Home‑based alternative: Structured home‑based programs incorporating behavioral‑change techniques and remote monitoring (calls, logbooks, connected devices) are acceptable when supervised programs are unavailable (Class IIa). The American College of Cardiology and the European Society of Cardiology. 52
• Unstructured “just walk more” advice: Ineffective and should never be recommended (Class III). The American College of Cardiology. 51

Pharmacologic Therapy for Claudication Symptoms

• Cilostazol (first‑line): 100 mg twice daily improves symptoms and walking distance by ≈ 40–60 %; it is the only medication with Level A evidence for symptom relief (Class I, Level A). The American College of Cardiology. 51
• Pentoxifylline (second‑line): 400 mg three times daily may be used; provides modest benefit (≈ 20–25 % improvement) and is Class IIb. The American College of Cardiology. 51
• Ineffective agents: L‑arginine, propionyl‑L‑carnitine, ginkgo biloba, and chelation therapy lack proven efficacy and should not be prescribed (Class III). The American College of Cardiology. 51

Indications and Strategies for Revascularization

• General indication criteria (Class I, Level A): Revascularization is appropriate only when all of the following are met:
• Contraindication: Revascularization is not indicated for asymptomatic PAD or solely to prevent progression to critical limb ischemia (Class III Harm). The American College of Cardiology and the European Society of Cardiology. 52

Anatomic‑Specific Strategies

• Aorto‑iliac disease:

  • Endovascular‑first for short (<5 cm) lesions (Class I). The American College of Cardiology. 52
  • Primary stenting effective for common iliac artery stenosis/occlusion (Class I). The American College of Cardiology. 51
  • Provisional stenting of external iliac arteries when balloon angioplasty leaves residual gradient > 10 mmHg, > 50 % stenosis, or flow‑limiting dissection (Class I). The American College of Cardiology. 51

• Femoropopliteal disease:

  • Drug‑eluting balloons or stents are first‑choice devices for endovascular treatment (Class I). The American College of Cardiology and the European Society of Cardiology. 52
  • Endovascular‑first for short (<25 cm) lesions (Class I). The American College of Cardiology. 52
  • For long (≥25 cm) lesions in low‑risk surgical patients with suitable autologous vein and life expectancy > 2 years, open bypass surgery with vein conduit is preferred (Class I). The American College of Cardiology. 52
  • Primary stenting in femoral, popliteal, or tibial arteries is not recommended except as salvage after failed balloon angioplasty (Class III). The American College of Cardiology. 51

• Infrapopliteal disease:

  • Treatment of severely impaired infrapopliteal outflow may be considered during the same session as femoropopliteal intervention for severe claudication (Class IIa). The European Society of Cardiology. 53

Post‑Revascularization Management

• Continue supervised exercise as adjunct therapy after endovascular revascularization (Class I). The American College of Cardiology. 51
• Dual‑pathway inhibition: Add rivaroxaban 2.5 mg twice daily to aspirin in high‑risk patients with low bleeding risk to further reduce cardiovascular and limb events (Class I, Level A). The American College of Cardiology and the European Society of Cardiology. 52

Critical Pitfalls to Avoid

• Do not proceed to revascularization without completing ≥3 months of supervised exercise + optimal medical therapy (Class III). The American College of Cardiology and the European Society of Cardiology. 52
• Do not withhold cilostazol in eligible patients without heart failure (Level A evidence). The American College of Cardiology. 51
• Do not add warfarin to antiplatelet regimens unless another indication exists (e.g., atrial fibrillation); it increases bleeding without benefit (Class III Harm). The American College of Cardiology. 51
• Do not recommend unstructured “just walk more” programs (Class III). The American College of Cardiology. 51
• Do not perform primary stenting in femoral, popliteal, or tibial arteries except as salvage (Class III). The American College of Cardiology. 51
• Do not revascularize asymptomatic PAD (Class III Harm). The American College of Cardiology and the European Society of Cardiology. 52

Guideline Recommendations for Peripheral Arterial Disease Management

1. Mandatory Medical Therapy for All PAD Patients

• The American College of Cardiology/American Heart Association (ACC/AHA) recommends that every patient with peripheral artery disease receive high‑intensity statin therapy targeting LDL < 1.4 mmol/L (≈55 mg/dL), antiplatelet therapy, and supervised exercise training before any revascularization is considered. 54
• ACC/AHA advises clopidogrel 75 mg daily as the preferred antiplatelet agent in PAD, providing an additional 24 % relative risk reduction in cardiovascular events compared with aspirin. 54
• If clopidogrel is contraindicated, aspirin 75–100 mg daily is an acceptable alternative. [54][55]
• For high‑risk PAD patients after revascularization who have low bleeding risk, the ESC recommends adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily (dual‑pathway inhibition) to further reduce cardiovascular and limb events. [55][56]
• ACC/AHA cautions against adding warfarin to antiplatelet regimens unless another indication exists (e.g., atrial fibrillation), because it markedly increases major bleeding without cardiovascular benefit. [54][55]
• ACC/AHA mandates high‑intensity statin therapy for all PAD patients regardless of baseline LDL‑C, with the LDL goal < 1.4 mmol/L. [54][55]56
• Statin therapy improves walking distance in claudication by approximately 20–25 %. 55
• If LDL goals are not met with maximally tolerated statin + ezetimibe, the ESC recommends adding bempedoic acid or a PCSK9 inhibitor. 55
• ACC/AHA sets a blood‑pressure target < 130/80 mmHg, recommending ACE inhibitors or ARBs as first‑line agents because they confer additional ischemic‑event reduction beyond blood‑pressure lowering. 54
• ACC/AHA advises a glycemic target HbA1c < 7 % in diabetic PAD patients to reduce microvascular complications. [54][55]
• For diabetic PAD, the ESC recommends adding SGLT2 inhibitors or GLP‑1 receptor agonists with proven cardiovascular benefit, independent of baseline HbA1c. 55
• ACC/AHA requires tobacco‑use assessment at every visit and provision of behavioral counseling with a personalized quit plan. 54
• When not contraindicated, the ESC suggests offering varenicline, bupropion, or nicotine‑replacement therapy for smoking cessation. 54

2. Supervised Exercise Training (SET)

• The ESC states that supervised exercise training is mandatory before any revascularization attempt and yields a 50–200 % improvement in maximal walking distance, far exceeding the 20–60 % gain from drug therapy alone. [54][55]56
• SET program specifications (ESC):
  
  • Sessions of 30–45 minutes, ≥ 3 times per week, for a minimum of 12 weeks. [**54][55]56
  • Intensity: walk to near‑maximal pain (Borg 14–17 or 77–95 % maximal heart rate), rest until pain resolves, then repeat. [**54][55]56
  • Primary modality: treadmill or track walking; resistance training may be added but does not replace walking. [54]**
• If a supervised program is unavailable, the ESC accepts structured home‑based programs that incorporate behavioral‑change techniques and remote monitoring (calls, logbooks, connected devices). 54
• Unstructured “just walk more” advice is ineffective and should be avoided. 54

3. Pharmacologic Therapy for Intermittent Claudication

• The ACC/AHA gives Level A evidence that cilostazol 100 mg twice daily improves symptoms and walking distance by 40–60 % in patients with lifestyle‑limiting claudication who do not have heart failure. [54][55]56
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy, offering modest benefit (~20–25 % improvement). 54
• L‑arginine, propionyl‑L‑carnitine, ginkgo biloba, and chelation therapy lack proven efficacy and should not be prescribed. 54

4. Indications for Revascularization in Intermittent Claudication

• The ESC requires that all four criteria be met before revascularization:
• Revascularization is NOT indicated for asymptomatic PAD or solely to prevent progression to critical limb‑threatening ischemia; it offers no benefit and may cause harm. [54][55]56

5. Revascularization Strategies by Anatomic Location

5.1 Aorto‑Iliac Disease

• ESC endorses an endovascular‑first approach for short (< 5 cm) occlusive aorto‑iliac lesions. [54][55]56
• Primary stenting is effective for common iliac artery stenosis and occlusion. [54][56]
• Provisional stenting of the external iliac artery is advised when balloon angioplasty leaves a residual pressure gradient, > 50 % stenosis, or flow‑limiting dissection. 54
• Measure trans‑lesional pressure gradients (with and without vasodilation) for iliac stenoses of 50–75 % diameter before deciding on intervention. 54

5.2 Femoropopliteal Disease

• For short lesions (< 25 cm), ESC recommends an endovascular‑first strategy using drug‑eluting balloons or stents as first‑choice devices. [55][56]
• Primary stenting in femoral, popliteal, or tibial arteries is NOT recommended except as salvage after failed balloon angioplasty. 54
• For long lesions (≥ 25 cm) in patients with low surgical risk, available autologous great saphenous vein, and life expectancy > 2 years, ACC/AHA prefers open bypass surgery with autologous vein. [55][56]
• Autologous saphenous vein is the conduit of choice for femoropopliteal bypass. [55][56]
• In high‑risk surgical patients, endovascular therapy may be considered despite lower durability. [55][56]

5.3 Infrapopliteal (Below‑the‑Knee) Disease

• When femoropopliteal revascularization is performed for severe claudication with substantially impaired outflow, ESC advises treating below‑the‑knee arteries during the same procedure. [55][56]

6. Post‑Revascularization Management

• ACC/AHA recommends continuation of supervised exercise training as adjunct therapy after endovascular revascularization. 54
• In high‑risk patients with low bleeding risk, ESC advises adding dual‑pathway inhibition (rivaroxaban 2.5 mg twice daily + aspirin 100 mg daily) to further reduce cardiovascular and limb events. [55][56]

7. Critical Limb‑Threatening Ischemia (CLTI)

• ESC defines CLTI as chronic (≥ 2 weeks) ischemic rest pain, non‑healing wound/ulcer, or gangrene with ankle pressure < 50 mmHg, toe pressure < 30 mmHg, or transcutaneous oxygen pressure < 30 mmHg. 55
• Early recognition and immediate referral to a multidisciplinary vascular specialist team are mandatory for limb salvage (ACC/AHA/ESC). [54][55]56
• ESC recommends using the WIfI scoring system to quantify amputation risk. [55][56]
• Optimizing glycemic control in diabetic CLTI patients is advised (ESC). [55][56]
• Off‑loading of mechanical stress is required to promote ulcer healing (ESC). [55][56]
• Systemic antibiotics should be started promptly when ulcerations are infected (ACC/AHA). 54
• Referral to specialized wound‑care providers for skin breakdown is recommended (ACC/AHA). 54

Revascularization in CLTI

• ESC states that revascularization should be performed as soon as anatomically feasible for limb salvage. [55][56]
• For infrapopliteal disease, autologous great saphenous vein bypass is the preferred revascularization method (ESC). [55][56]
• Stem‑cell or gene therapies are not indicated for CLTI (ESC). [55][56]

Surveillance After CLTI Treatment

• ACC/AHA recommends follow‑up at least twice yearly with a vascular specialist due to high recurrence rates. 54
• Direct foot examination (shoes and socks removed) at regular intervals, with verbal and written self‑surveillance instructions, is advised (ACC/AHA). 54

8. Acute Limb Ischemia

• When a neurological deficit is present, ESC mandates urgent revascularization immediately. [55][56]
• If no neurological deficit, revascularization should occur within hours after imaging, based on individual assessment (ESC). [55][56]
• Heparin and analgesics should be administered immediately (ESC). [55][56]

9. Critical Pitfalls to Avoid

• Do not proceed to revascularization for claudication without completing ≥ 3 months of supervised exercise and optimal medical therapy (ACC/AHA/ESC). [54][55]56
• Do not withhold cilostazol in eligible claudication patients without heart failure; it has Level A evidence for symptom improvement (ACC/AHA). 54
• Do not add warfarin to antiplatelet regimens unless another indication exists; it increases bleeding without cardiovascular benefit (ACC/AHA/ESC). [54][55]
• Do not recommend unstructured “just walk more” programs; they are ineffective (ACC/AHA). 54
• Do not perform primary stenting in femoral, popliteal, or tibial arteries except as salvage after failed balloon angioplasty (ACC/AHA). 54
• Do not revascularize asymptomatic PAD; there is no benefit and potential harm (ACC/AHA/ESC). [54][55]56

Management of Borderline Ankle‑Brachial Index (ABI) with Claudication

Diagnostic Classification

• An ABI of 1.1 is considered normal (range 1.00–1.40) according to the American Heart Association/American College of Cardiology (ACC) guidance. 57
• An ABI of 0.94 falls into the borderline abnormal range (0.91–0.99) and, when accompanied by claudication, signals the need for further testing (ACC). [58][57]
• An ABI < 0.90 confirms peripheral artery disease (PAD); however, borderline values (0.91–0.99) with symptoms also require additional evaluation (ACC, European Society of Cardiology). [57][59]

Immediate Diagnostic Testing for Borderline ABI

• Exercise treadmill testing with post‑exercise ABI is recommended for patients with borderline resting ABI and claudication to uncover hemodynamically significant PAD (ACC, ESC). [57][59]
• Diagnostic threshold: a post‑exercise ankle pressure drop > 30 mm Hg or a post‑exercise ABI reduction > 20 % confirms PAD (ACC). 57
• The test should follow a standardized treadmill protocol, with bilateral ankle pressures measured beginning 1 minute after exercise cessation (ESC). 59

First‑Line Non‑Invasive Imaging

• Duplex ultrasound is the preferred initial imaging modality to verify arterial stenoses and grade anatomic severity (ESC, ACC). [60][61]
• Toe‑brachial index (TBI) is indicated only when the resting ABI exceeds 1.40 (suggesting non‑compressible vessels); it is not applicable in the present borderline scenario (ESC, ACC). [60][57]

Mandatory Medical Therapy

Antiplatelet Strategy

• Clopidogrel 75 mg daily is the preferred first‑line antiplatelet agent for PAD, providing a 24 % relative risk reduction in cardiovascular events versus aspirin (ACC).
• Aspirin 75–100 mg daily is an acceptable alternative when clopidogrel is contraindicated (ACC). [58][62]
• Warfarin must not be added to antiplatelet therapy unless another indication (e.g., atrial fibrillation) exists, as it raises major bleeding without cardiovascular benefit (ACC). [58][62]

Lipid Management

• High‑intensity statin therapy is mandatory for all PAD patients, targeting LDL‑C < 1.4 mmol/L (≈55 mg/dL) regardless of baseline levels (ESC). 60
• If the LDL goal is not reached with maximally tolerated statin + ezetimibe, bempedoic acid or a PCSK9 inhibitor should be added (ESC). 60

Glycemic Control (Diabetic Patients)

• Aim for HbA1c < 7 % to lower microvascular complications (ESC). 60
• Incorporate SGLT2 inhibitors or GLP‑1 receptor agonists with proven cardiovascular benefit when indicated (ESC). 60

Smoking Cessation

• Assess tobacco use at every encounter and provide behavioral counseling plus pharmacologic aids (varenicline, bupropion, nicotine‑replacement therapy) when not contraindicated (ACC). [58][62]

First‑Line Therapy for Claudication

Supervised Exercise Training

• Structured supervised exercise is the initial therapy before any revascularization attempt, yielding a 50–200 % improvement in maximal walking distance (ACC). [58][62]
• Program specifications (ACC):
  
  • Session duration: 30–45 minutes. [58][62]
  • Frequency: ≥ 3 sessions per week. [58][62]
  • Minimum program length: 12 weeks. [58][62]

Pharmacologic Adjuncts

• Cilostazol 100 mg twice daily improves symptoms and walking distance by 40–60 %; Level A evidence; indicated for all patients with lifestyle‑limiting claudication without heart failure (ACC). [58][62]
• Pentoxifylline 400 mg three times daily may be used as second‑line therapy, offering a modest 20–25 % walking‑distance gain (ACC). [58][62]
• Supplements such as L‑arginine, propionyl‑L‑carnitine, ginkgo biloba, and chelation therapy lack proven efficacy and should not be prescribed (ACC). 58

Indications and Contraindications for Revascularization

• Revascularization is not indicated for a borderline ABI alone without disabling symptoms after optimal medical therapy, as it provides no benefit and may cause harm (ACC, ESC). [63][59]
• Revascularization should only be considered after ≥ 3 months of supervised exercise and optimal medical therapy, persistent disabling claudication, and favorable lesion anatomy (low procedural risk, high likelihood of durable success) (ESC).

Follow‑Up and Monitoring

• Re‑measure ABI at 3 months to track disease progression (ESC). 60
• If disabling symptoms persist despite optimal therapy, obtain duplex ultrasound or CT/MR angiography to delineate lesion anatomy and guide revascularization planning (ESC, ACC). [60][61]

Common Pitfalls to Avoid

• Do not proceed to revascularization without completing ≥ 3 months of supervised exercise and optimal medical therapy (ESC). 59
• Do not withhold cilostazol in eligible patients without heart failure; Level A evidence supports its use (ACC). [58][62]
• Do not add warfarin to antiplatelet regimens unless another indication exists (ACC). [58][62]
• Do not rely solely on resting ABI to exclude PAD when claudication is present; exercise testing is required for borderline values (ACC, ESC). [57][59]